Patents by Inventor Richard Trovato

Richard Trovato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purine-core inhibitors of HSP90 and their use in treating cancer
    Patent number: 8476285
    Abstract: The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L1, L2, are as defined herein.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: July 2, 2013
    Assignee: Myrexis, Inc.
    Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • Therapeutic Compounds and Their Use in Treating Diseases and Disorders
    Publication number: 20100292255
    Abstract: The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.
    Type: Application
    Filed: May 14, 2010
    Publication date: November 18, 2010
    Applicant: Myriad Pharmaceuticals, Inc.
    Inventors: Ashok C. Bajji, Se-Ho Kim, Rajendra Tangallapally, Benjamin J. Markovitz, Richard Trovato, Mark B. Anderson, Daniel A. Wettstein, Mark D. Shenderovich
  • THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER
    Publication number: 20100016586
    Abstract: The invention relates to compounds of Formulae I-III and their therapeutic uses.
    Type: Application
    Filed: June 30, 2009
    Publication date: January 21, 2010
    Applicant: Myriad Genetics, Incorporated
    Inventors: ASHOK C. BAJJI, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • Therapeutic compounds and their use in cancer
    Patent number: 7595401
    Abstract: The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: September 29, 2009
    Assignee: Myriad Pharmaceuticals, Inc.
    Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • PHARMACEUTICAL COMPOSITION AND METHOD
    Publication number: 20090155903
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other A?42-related diseases and disorders.
    Type: Application
    Filed: March 21, 2005
    Publication date: June 18, 2009
    Applicant: Myriad Genetics, Incorporated
    Inventors: Rachel M. Slade, Warren S. Weiner, Eric Delmar, Yevgeniya Klimova, Richard Trovato
  • THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER
    Publication number: 20070299258
    Abstract: The invention relates to compounds of Formulae I-III and their therapeutic uses.
    Type: Application
    Filed: May 14, 2007
    Publication date: December 27, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Ashok Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark Anderson, Daniel Wettstein, Mark Shenderovich, John Vanecko
  • Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
    Patent number: 7053104
    Abstract: The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: May 30, 2006
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Bradford C. Van Wagenen, Scott T. Moe, Daryl L. Smith, Susan M. Sheehan, Irina Shcherbakova, Ruth Walton, Richard Trovato, Robert Barmore, Eric G. Delmar, Thomas M. Stormann
  • Inorganic ion receptor-active compounds
    Patent number: 6710088
    Abstract: The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: March 23, 2004
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Scott T. Moe, Bradford C. Van Wagenen, Eric G. DelMar, Richard Trovato, Manuel F. Balandrin
  • Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
    Publication number: 20030013715
    Abstract: The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Application
    Filed: August 5, 2002
    Publication date: January 16, 2003
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Bradford C. Van Wagenen, Scott T. Moe, Daryl L. Smith, Susan M. Sheehan, Irina Shcherbakova, Ruth Walton, Richard Trovato, Robert Barmore, Eric G. Delmar, Thomas M. Stormann
  • Inorganic ion receptor-active compounds
    Publication number: 20030008876
    Abstract: The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor.
    Type: Application
    Filed: July 22, 2002
    Publication date: January 9, 2003
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Scott T. Moe, Bradford C. Van Wagenen, Eric G. DelMar, Richard Trovato, Manuel F. Balandrin
  • Inorganic ion receptor active compounds
    Patent number: 6342532
    Abstract: The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor.
    Type: Grant
    Filed: October 6, 1999
    Date of Patent: January 29, 2002
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Scott T. Moe, Bradford C. Van Wagenen, Eric G. DelMar, Richard Trovato, Manuel F. Balandrin
  • Inorganic ion receptor active compounds
    Patent number: 5981599
    Abstract: The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: November 9, 1999
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Scott T. Moe, Bradford C. Van Wagenen, Eric G. DelMar, Richard Trovato, Manuel F. Balandrin